Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 469, Issue 4, 2016, Pages 1075-1082

  He, Guodong ^a,b   He, Guoliang ^a   Zhou, Riyong ^a   Pi, Zhibing ^a   Zhu, Tianqi ^a   Jiang, Liuming ^a   Xie, Yubo ^b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; Colon cancer; Mitochondrial dysfunction; ROS; Shikonin

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; SHIKONIN; ANTINEOPLASTIC AGENT; HERBACEOUS AGENT; NAPHTHOQUINONE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIZATION; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LITHOSPERMUM; LITHOSPERMUM ERYTHRORHIZON; LOW DRUG DOSE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NONHUMAN; NUDE MOUSE; OXIDATIVE STRESS; PLANT ROOT; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; COLONIC NEOPLASMS; DRUG EFFECTS; HT 29 CELL LINE; METABOLISM; MOUSE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; COLONIC NEOPLASMS; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; FEMALE; HT29 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NAPHTHOQUINONES; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME;

EID: 84957849807     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.12.100     Document Type: Article

References (33)

1. T. Gansler, P.A. Ganz, M. Grant, F.L. Greene, P. Johnstone, M. Mahoney, L.A. Newman, W.K. Oh, C.R. Thomas Jr., M.J. Thun, A.J. Vickers, R.C. Wender, and O.W. Brawley Sixty years of CA: a cancer journal for clinicians, CA A Cancer J. For Clin. 60 2010 345 350
2. N. Kemeny, K. Israel, D. Niedzwiecki, D. Chapman, J. Botet, B. Minsky, V. Vinciguerra, R. Rosenbluth, B. Bosselli, C. Cochran, and et al. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer J. of Clinical Oncol. Off. J. Am. Soc. of Clin. Oncol. 8 1990 313 318
3. P. Bragado, A. Armesilla, A. Silva, and A. Porras Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation, Apoptosis An Int. J. Program. Cell Death 12 2007 1733 1742
4. L. Galluzzi, I. Vitale, J. Michels, C. Brenner, G. Szabadkai, A. Harel-Bellan, M. Castedo, and G. Kroemer Systems biology of cisplatin resistance: past, present and future Cell Death Dis. 5 2014 e1257
5. M.E. Valsecchi Combined Nivolumab and Ipilimumab or monotherapy in Untreated Melanoma N. Engl. J. Med. 373 2015 1270
6. M. Harada, J. Benito, S. Yamamoto, S. Kaur, D. Arslan, S. Ramirez, R. Jacamo, L. Platanias, H. Matsushita, T. Fujimura, S. Kazuno, K. Kojima, Y. Tabe, and M. Konopleva The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression Oncotarget 6 2015 37930 37947
7. Y.L. Wu, C. Zhou, C.P. Hu, J. Feng, S. Lu, Y. Huang, W. Li, M. Hou, J.H. Shi, K.Y. Lee, C.R. Xu, D. Massey, M. Kim, Y. Shi, and S.L. Geater Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Lancet. Oncol. 15 2014 213 222
8. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature reviews Drug Discov. 8 2009 579 591
9. Y. Ma, J. Zhang, Q. Zhang, P. Chen, J. Song, S. Yu, H. Liu, F. Liu, C. Song, D. Yang, and J. Liu Adenosine induces apoptosis in human liver cancer cells through ROS production and mitochondrial dysfunction Biochem. Biophys. Res. Commun. 448 2014 8 14
10. L. Raj, T. Ide, A.U. Gurkar, M. Foley, M. Schenone, X. Li, N.J. Tolliday, T.R. Golub, S.A. Carr, A.F. Shamji, A.M. Stern, A. Mandinova, S.L. Schreiber, and S.W. Lee Selective killing of cancer cells by a small molecule targeting the stress response to ROS Nature 475 2011 231 234
11. F. Ye, H. Wang, L. Zhang, Y. Zou, H. Han, and J. Huang Baicalein induces human osteosarcoma cell line MG-63 apoptosis via ROS-induced BNIP3 expression, tumour biology J. Int. Soc. Oncodevelopmental Biol. Med. 36 2015 4731 4740
12. W. Fiskus, N. Saba, M. Shen, M. Ghias, J. Liu, S.D. Gupta, L. Chauhan, R. Rao, S. Gunewardena, K. Schorno, C.P. Austin, K. Maddocks, J. Byrd, A. Melnick, P. Huang, A. Wiestner, and K.N. Bhalla Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia Cancer Res. 74 2014 2520 2532
13. T. Xiang, L. Du, P. Pham, B. Zhu, and S. Jiang Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway Cancer Lett. 364 2015 79 88
14. P. Zou, M. Chen, J. Ji, W. Chen, X. Chen, S. Ying, J. Zhang, Z. Zhang, Z. Liu, S. Yang, and G. Liang Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer Oncotarget 6 2015 36505 36521
15. N.C. Yip, I.S. Fombon, P. Liu, S. Brown, V. Kannappan, A.L. Armesilla, B. Xu, J. Cassidy, J.L. Darling, and W. Wang Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties Br. J. Cancer 104 2011 1564 1574
16. D. Duan, B. Zhang, J. Yao, Y. Liu, and J. Fang Shikonin targets cytosolic thioredoxin reductase to induce ROS-mediated apoptosis in human promyelocytic leukemia HL-60 cells Free Radic. Biol. Med. 70 2014 182 193
17. X. Chen, L. Yang, J.J. Oppenheim, and M.Z. Howard Cellular pharmacology studies of shikonin derivatives, phytotherapy research PTR 16 2002 199 209
18. X. Mao, C.R. Yu, W.H. Li, and W.X. Li Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells Cell Res. 18 2008 879 888
19. S. Fulda, E. Meyer, C. Friesen, S.A. Susin, G. Kroemer, and K.M. Debatin Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis Oncogene 20 2001 1063 1075
20. J.C. Sharpe, D. Arnoult, and R.J. Youle Control of mitochondrial permeability by Bcl-2 family members Biochimica Biophysica Acta 1644 2004 107 113
21. W. Chen, Z. Zhao, L. Li, B. Wu, S.F. Chen, H. Zhou, Y. Wang, and Y.Q. Li Hispolon induces apoptosis in human gastric cancer cells through a ROS-mediated mitochondrial pathway Free Radic. Biol. Med. 45 2008 60 72
22. W.R. Huang, Y. Zhang, and X. Tang Shikonin inhibits the proliferation of human lens epithelial cells by inducing apoptosis through ROS and caspase-dependent pathway Molecules 19 2014 7785 7797
23. R. Salazar, and F. Ciardiello Optimizing anti-EGFR therapy in colorectal cancer Off. J. Am. Assoc. Cancer Res. 21 2015 5415 5416
24. E.J. Lipson, P.M. Forde, H.J. Hammers, L.A. Emens, J.M. Taube, and S.L. Topalian Antagonists of PD-1 and PD-L1 in cancer treatment Seminars Oncol. 42 2015 587 600
25. T. Boulikas, and M. Vougiouka Cisplatin and platinum drugs at the molecular level. (review) Oncol. Rep. 10 2003 1663 1682
26. H.J. Cho, J.K. Kim, K.D. Kim, H.K. Yoon, M.Y. Cho, Y.P. Park, J.H. Jeon, E.S. Lee, S.S. Byun, H.M. Lim, E.Y. Song, J.S. Lim, D.Y. Yoon, H.G. Lee, and Y.K. Choe Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells Cancer Lett. 237 2006 56 66
27. C.M. Rudin, Z. Yang, L.M. Schumaker, D.J. VanderWeele, K. Newkirk, M.J. Egorin, E.G. Zuhowski, and K.J. Cullen Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance Cancer Res. 63 2003 312 318
28. M. Sprauten, T.H. Darrah, D.R. Peterson, M.E. Campbell, R.E. Hannigan, M. Cvancarova, C. Beard, H.S. Haugnes, S.D. Fossa, J. Oldenburg, and L.B. Travis Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer J. of Clinical Oncol. Off. J. Am. Soc. Clin. Oncol. 30 2012 300 307
29. Y. Du, J. Gong, X. Tian, X. Yan, T. Guo, M. Huang, B. Zhang, X. Hu, H. Liu, Y. Wang, J. Li, and M. Li Japonicone A inhibits the growth of non-small cell lung cancer cells via mitochondria-mediated pathways, tumour biology J. Int. Soc. Oncodevelopmental Biol. Med. 36 2015 7473 7482
30. J. Henry-Mowatt, C. Dive, J.C. Martinou, and D. James Role of mitochondrial membrane permeabilization in apoptosis and cancer Oncogene 23 2004 2850 2860
31. M.H. Harris, and C.B. Thompson The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability Cell Death Differ. 7 2000 1182 1191
32. S. Cory, and J.M. Adams The Bcl2 family: regulators of the cellular life-or-death switch, nature reviews Cancer 2 2002 647 656
33. P. Zou, J. Zhang, Y. Xia, K. Kanchana, G. Guo, W. Chen, Y. Huang, Z. Wang, S. Yang, and G. Liang ROS generation mediates the anti-cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer Oncotarget 6 2015 5860 5876